Gonzalo Vegas
Director, Clinical Imaging, Early Clinical Development AstraZeneca
Clinical Imaging Scientist with over two decades of expertise in optimizing CT, MRI, and ultrasound protocols to minimize confounding factors, enhancing biomarker identification, assessing disease severity, and advancing patient stratification across various conditions, particularly pulmonary diseases. Demonstrated academic excellence with a remarkable publication record, successful patent licensing, and leadership in fostering productive collaborations with distinguished both academic and private sector scientific matrixed teams. Highly regarded by peers and direct reports for a supportive, collaborative approach to driving innovative research.
Seminars
Thursday 17th September 2026
Panel Discussion: Thinking Beyond Exacerbations & Lung Function to Define the Future of Clinical Endpoints
9:30 am
- Should COPD drug development move beyond exacerbation reduction as the dominant endpoint, and what alternative measures could better capture meaningful clinical benefit?
- How clinically meaningful are early improvements in lung function, and could they serve as valid endpoints for evaluating acute COPD treatments?
- What additional endpoints could better reflect patient benefit, including symptom improvement, quality of life, or disease progression?
- How do regulatory expectations currently shape endpoint selection in COPD trials, and where might there be flexibility for innovation?
- What strategies can developers use to demonstrate robust clinical value when proposing novel endpoints to regulators and payers?
